Back to search
FDAFDA · Food and drugs·Recall number D-0009-2025

Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05.

Published October 23, 2024 · Recall initiated: October 10, 2024

Summary

FDA records drug Class II recall D-0009-2025, published October 23, 2024 and initiated October 10, 2024. Recalling firm: Breckenridge Pharmaceutical, Inc; Status: Completed; Reported quantity: 7,107 bottles; Lot: Lot #: 220128, Exp. Date 12/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

What to do

Voluntary: Firm initiated · Letter

Get an email if DULOXETINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DULOXETINE
Manufacturer
Breckenridge Pharmaceutical, Inc
Distributor
Product was distributed nationwide within the United States
Lot
Lot #: 220128, Exp. Date 12/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05. recalled?

Yes. FDA published recall D-0009-2025 on October 23, 2024. Reported hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DULOXETINE.